加用β_2受体激动剂治疗支气管扩张症的临床疗效分析  

A clinical analysis of treating bronchiectasis with β_2-receptor activator

作　　者：叶汉深[1] 梁力[1] 薛松[1] 

机构地区：[1]解放军第四二一医院,广东广州510318

出　　处：《海军医学杂志》2003年第4期298-299,共2页Journal of Navy Medicine

摘　　要：目的 :探讨加用口服 β2 受体激动剂对支气管扩张症的临床疗效。方法 :将近 5年在我院住院的支气管扩张症患者 6 2例 ,随机分为治疗组 (31例 )与对照组 (31例 ) ,对照组常规给予抗感染、排痰、雾化吸入及其他对症治疗 ,治疗组在常规治疗的基础上口服 β2 受体激动剂 (美喘清 ) ,对比观察 2组肺功能 (VC、FVC、FEV1)变化情况及多项康复指标。结果 :治疗组在第 2～ 3天肺功能即有明显改善 ,对照组约第 5天后方有明显改善 ,且治疗组症状控制时间、咯血者止血时间及住院天数均少于对照组。结论 :对支气管扩张症患者 ,尽管无气喘症状也应适当给予 β2Objective: To observe the clinical curative effect of β 2-receptor activator on bronchiectasis. Methods: 62 in-patients with bronchiectasis were divided randomly into the treatment group (TG) and the control group (CG). The CG was treated with antibiotics, reducing sputum, atomization and symptom control remedy, and the TG with routine treatment and β 2-receptor activator (procaterol hydrochloride). Lung functions (VC, FVC and FEV 1) and other indexes of rehabilitations were observed in our research. Results: The lung functions of the TG improved evidently on the second day or the third day, whereas those of the CG on the fifth day. The symptom controls, bleeding control time, and in-hospital time of the TG were shorter than those of the CG. Conclusion: Though some bronchiectasis cases do not have asthmas, appropriate β 2-receptor activator should be given to them.

关 键 词：支气管扩张症 Β2受体激动剂 治疗 抗生素 肺功能 

分 类 号：R562.22[医药卫生—呼吸系统]